Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2011, with the report dated January 4, 2011. The filing serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights.
- Issued Share Capital (as of Dec 31, 2010): 5,670,458,177 Ordinary shares of 25p each.
- Treasury Shares: 474,194,158 Ordinary shares.
- Total Voting Rights: 5,196,264,019.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document is a static notification of capital structure as of December 31, 2010.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements or risk disclosures.
Key Facts for Investor Verification
- Verify the total number of voting rights (5,196,264,019) to determine notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
- Confirm the number of shares held in Treasury (474,194,158) which are excluded from the voting rights count.
- Note that this filing does not contain financial performance data; investors should refer to Form 20-F for comprehensive financial results.